West Coast EditorCeregene Inc. is keeping U.S. and Canadian rights to its Phase II drug for Parkinson's disease and getting $25 million up front plus as much as $125 million in milestone payments, along with 50 percent of worldwide Phase III costs covered, through a deal with Genzyme Corp, which will pay royalties on sales in other territories. (BioWorld Today)